Enterprise Value

-4.143M

Cash

65.92M

Avg Qtr Burn

-8.11M

Short % of Float

1.81%

Insider Ownership

5.56%

Institutional Own.

13.18%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Rilvegostomig (PD-1/TIGIT) Details
Non-small cell lung carcinoma, Cancer, Hepatobiliary cancer

Phase 3

Data readout

COM701 + Opdivo (nivolumab) +/- BMS-986207 Details
Ovarian cancer, Cancer, Endometrial cancer

Phase 1/2

Update

COM701 + Opdivo (nivolumab) Details
Solid tumor/s, Cancer, Metastatic breast cancer

Phase 1b

Update

COM902 (TIGIT) Details
Cancer, Advanced malignancies

Phase 1

Data readout

COM701+COM902 +Pembrolizumab Details
Cancer, Platinum-resistant ovarian cancer

Phase 1

Data readout

COM701+COM902 +Pembrolizumab Details
Cancer, Colorectal cancer

Phase 1

Data readout

COM701 (PVRIG) Details
Ovarian cancer, Colorectal cancer , Non-small cell lung carcinoma, Breast cancer, Endometrial cancer, Cancer

Failed

Discontinued